Metronidazole Aztreonam

Aztreonam + vancomycin + metronidazole 1 g every 8 hours + 1 5 mg/kg every 12 hours + 500 mg every 6 hours Option for penicillin-allergic patients... 

Clindamycin and metronidazole appear to be equivalent in efficacy when combined with agents effective against aerobic gram-negative bacilli (e.g., gentamicin or aztreonam). 

Cirrhosis Peritoneal Cefotaxime Regimen based on organism isolated 1. Add clindamycin or metronidazole if anaerobes are suspected 2. Other third-generation cephalosporins, extended-spectrum penicillins, aztreonam, and imipenem as alternatives 3. Aminoglycoside with antipseudomonal penicillin... 

Other Imipenem/cilistatin, meropenem, ertapenem, or extended-spectrum penicillins with B-lactamase inhibitor 1. Ciprofloxacin with metronidazole 2. Aztreonam with clindamycin or metronidazole 3. Antianaerobic cephalosporins.3... 

Gangrenous or Imipenem/cilastatin, meropenem, ertapenem, 1. Aztreonam with clindamycin or metronidazole... 

In penicillin-allergic patients, metronidazole or clindamycin plus either a fluoroquinolone, aztreonam, or, possibly, a third-generation cephalosporin is appropriate. 

Aztreonam (Azactam) Clindamycin (Cleocin, Cleocin-T, others) Fosfomycin (Monurol) Linezolid (Zyvox) Metronidazole (Flagyl, MetroGel)... 

Aztreonam Incompatibility of aztreonam has been reported with metronidazole, nafcillin, and vancomycin.1... 

Vancomycin, daptomycin or linezolid (to cover staphylococci including methicillin-resistant Staphylococcus aureus (MRSA), streptococci and enterococci) plus metronidazole (to cover anaerobes) plus gentamicin, ciprofloxacin, ceftazidime or aztreonam (to cover Gram-negative organisms including Pseudomonas). 

Ciprofloxacin in combination with metronidazole Aztreonam plus metronidazole... 

Antimicrobials. Aztreonam, cefamandole, chloramphenicol, ciprofloxacin, co-trimoxazole, erythromycin, fluconazole, itraconazole, ketoconazole, metronidazole, miconazole, ofloxacin and sulphonamides (including co-trimoxazole) increase anticoagulant effect by mechanisms that include interference with warfarin or vitamin K metabolism. Rifampicin and griseofulvin accelerate warfarin metabolism (enzyme induction) and reduce its effect. Intensive broad-spectrum antimicrobials, e.g. eradication regimens for Helicobacter pylori (see p. 630), may increase sensitivity to warfarin by reducing the intestinal flora that produce vitamin K. 

There appear to be no clinically significant pharmacokinetic interactions between aztreonam and amikacin, cefradine, clindamycin, gentamicin, metronidazole or nafcillin. 

Metronidazole has poor activity against the aerobic and microaerophUic streptococci aztreonam and ceftazidime have no and poor activity against aerobic gram-positive oropharyngeal flora respectively. 

---